List of Excipients in Branded Drug AFTERPILL

« Back to Dashboard

Generic Drugs Containing AFTERPILL

Company	Ingredient	NDC	Excipient
Syzygy Healthcare Solutions LLC PO Box 588 Westport CT 06880	levonorgestrel	64122-605	LACTOSE MONOHYDRATE
Syzygy Healthcare Solutions LLC PO Box 588 Westport CT 06880	levonorgestrel	64122-605	MAGNESIUM STEARATE
Syzygy Healthcare Solutions LLC PO Box 588 Westport CT 06880	levonorgestrel	64122-605	POVIDONE K30

What are the Most Frequently-Used Excipients in AFTERPILL?

# Of NDCs	Excipient
1	LACTOSE MONOHYDRATE
1	MAGNESIUM STEARATE
1	POVIDONE K30

AfterPill Excipient Strategy and Commercial Opportunities

Last updated: September 30, 2026

AfterPill is a low-complexity emergency contraceptive product containing levonorgestrel 1.5 mg in an immediate-release oral tablet. Its commercial advantage is unlikely to come from novel excipient technology. The strongest opportunities are low-cost manufacturing, reliable tablet performance, discreet distribution, private-label supply, rapid fulfillment and channel expansion.

The product has no meaningful active-ingredient patent barrier. Levonorgestrel emergency contraception is a mature generic category with multiple FDA-approved products and limited formulation differentiation. Excipient selection should therefore prioritize manufacturing robustness, dissolution performance, stability, regulatory familiarity and cost.

What is AfterPill and how is it regulated?

AfterPill is an emergency contraceptive tablet containing 1.5 mg of levonorgestrel. Levonorgestrel is a progestin used to reduce the risk of pregnancy after unprotected intercourse or contraceptive failure.

The FDA approved Plan B One-Step as a nonprescription emergency contraceptive and later permitted nonprescription access without age restrictions. Generic levonorgestrel emergency contraceptives can be approved through the abbreviated new drug application pathway when they demonstrate pharmaceutical equivalence and bioequivalence to the reference product.[1]

Product characteristic	AfterPill commercial profile
Active ingredient	Levonorgestrel
Strength	1.5 mg
Dosage form	Immediate-release oral tablet
Therapeutic category	Emergency contraception
Primary regulatory pathway	Generic drug pathway, subject to product-specific approval status
Administration	Single oral dose
Prescription status	Marketed for nonprescription access in the U.S.; channel and label status must be verified against current FDA records
Primary competitors	Plan B One-Step, Take Action, My Choice, EContra EZ, Option 2 and private-label levonorgestrel products

AfterPill’s commercial model has historically emphasized direct-to-consumer ordering and advance purchase. That model reduces the timing problem associated with emergency contraception, where a delay in access can reduce practical value.

What excipients are used in AfterPill?

Public product labeling identifies AfterPill as a conventional immediate-release levonorgestrel tablet. Publicly available labeling for levonorgestrel 1.5 mg products commonly identifies excipients such as lactose monohydrate, maize starch, povidone, colloidal silicon dioxide and magnesium stearate. The exact current AfterPill formulation should be confirmed against the latest FDA labeling and product packaging before use in regulatory, sourcing or litigation analysis.

Excipient class	Typical function in levonorgestrel tablets	Commercial rationale
Lactose monohydrate	Diluent and tablet mass builder	Low cost, broad supplier base and established oral-use history
Maize starch	Disintegrant and processing aid	Supports rapid tablet breakup and immediate release
Povidone	Binder	Improves granule or tablet cohesion at low dose
Colloidal silicon dioxide	Glidant and moisture-flow aid	Improves powder flow and blend uniformity
Magnesium stearate	Lubricant	Reduces ejection force and tooling friction

The excipient profile is strategically conservative. It uses familiar, compendial materials rather than a proprietary delivery platform. That approach is appropriate because the dose is small, the product is swallowed as a single tablet and the target performance is rapid and reproducible drug release.

How should the AfterPill excipient strategy be optimized?

The main formulation challenge is content uniformity. Levonorgestrel represents a small fraction of total tablet mass, so the manufacturing process must control segregation, blend uniformity and dose distribution.

Content uniformity

The formulation should use a validated premixing or geometric dilution process for levonorgestrel. Direct compression may be feasible if the active ingredient and excipient particle-size distributions are compatible. Wet or dry granulation can reduce segregation risk but adds processing steps, equipment requirements and moisture-control considerations.

Critical process variables include:

• Active-to-excipient premix time
• Blend uniformity
• Particle-size distribution
• Bulk and tapped density
• Lubrication time
• Compression force
• Tablet hardness and friability
• Packaging moisture exposure

For a low-dose tablet, excessive magnesium stearate or prolonged lubrication can slow disintegration and dissolution. Povidone concentration should be sufficient to produce durable tablets without creating a dense matrix that delays release.

Immediate-release performance

Emergency contraception does not require a sustained-release system. The commercial target is a tablet that disintegrates rapidly and releases levonorgestrel consistently across the product shelf life.

Starch-based disintegration is commercially attractive because it is inexpensive and familiar to regulators. A formulation using superdisintegrants such as croscarmellose sodium, crospovidone or sodium starch glycolate could provide faster or more consistent disintegration, but it would not automatically create a strong competitive position. Any change would require comparative dissolution work, stability studies and potentially a new regulatory filing or supplement.

Stability and packaging

Levonorgestrel tablet stability depends on the finished formulation, packaging system, temperature, humidity and manufacturing process. A low-cost bottle or blister package may be sufficient if stability data support it. Blister packaging can improve dose protection, portability and tamper evidence, while unit-dose cartons can support pharmacy, campus and vending channels.

Potential packaging priorities are:

1. Protection from humidity and heat.
2. Compact unit-dose presentation.
3. Clear expiration-date visibility.
4. Tamper evidence.
5. Discreet shipping.
6. Bar-code compatibility for pharmacy distribution.

Packaging can create more practical differentiation than excipient innovation. A unit-dose blister designed for vending machines, campus health centers or telehealth fulfillment may expand access without altering the drug formulation.

What commercial opportunities exist for AfterPill?

AfterPill has several commercial opportunities because the active ingredient is inexpensive, stable and widely understood by manufacturers. The product’s value proposition is based on access, convenience and price.

Direct-to-consumer and telehealth

Advance-purchase ordering is a natural fit for emergency contraception. Consumers may buy the product before it is needed, which supports household inventory and reduces dependence on pharmacy opening hours.

Telehealth providers can use AfterPill or a comparable levonorgestrel product in fulfillment programs. The principal commercial requirements are reliable inventory, compliant labeling, rapid shipping and appropriate medical-information content.

Private-label and institutional supply

The product is suitable for private-label arrangements with:

• Telehealth companies
• Pharmacy chains
• University health systems
• Public-health departments
• Employers offering reproductive-health benefits
• Nonprofit access programs
• Campus vending operators
• International distributors

Private-label economics will depend more on minimum order quantities, packaging configuration, quality agreements and distribution margins than on active pharmaceutical ingredient cost.

Multi-unit and convenience packaging

A single tablet is the standard therapeutic unit. Commercial pack configurations can still vary:

Format	Target channel	Opportunity
Single blister	Pharmacy and direct-to-consumer	Lowest price and simplest inventory
Two-pack	Household advance purchase	Convenience and repeat-use preparedness
Retail carton	Mass retail	Shelf visibility and brand recognition
Institutional multipack	Clinics and public-health programs	Lower packaging cost per dose
Discreet mailer	Telehealth	Privacy and delivery convenience
Vending-compatible pack	Campuses and public locations	24-hour access

A two-pack does not change the recommended single-dose regimen. Labeling must avoid implying that two tablets should be taken for one episode unless medically directed.

What patents protect AfterPill and levonorgestrel emergency contraception?

No active-ingredient patent appears to provide meaningful market exclusivity for a conventional levonorgestrel 1.5 mg emergency contraceptive tablet. Levonorgestrel is an established compound, and the core emergency-contraception market has long included generic products.

The relevant IP categories are:

IP category	Risk level for conventional AfterPill-type product	Assessment
Levonorgestrel composition patent	Low	Mature active ingredient with no practical new-drug exclusivity
1.5 mg immediate-release tablet	Low	Conventional dosage form
Basic excipient combination	Low to moderate	Risk depends on claim scope and jurisdiction; routine excipients generally provide weak differentiation
Method-of-use claims	Low to moderate	Emergency-contraception use is established; new population or regimen claims could differ
Packaging and dispensing system	Moderate	Potentially relevant for access, adherence or vending models
Manufacturing process	Moderate	Risk depends on proprietary granulation, crystallization or impurity-control claims
Branded trade dress	Moderate	Trademark and unfair-competition issues remain separate from patent freedom to operate

The Orange Book should be reviewed for the exact approved product, reference listed drug and any listed patents. The absence of a listed patent does not eliminate all patent risk, particularly for manufacturing processes, packaging systems or foreign markets.[2]

Are there formulation patents covering AfterPill?

A conventional mixture of levonorgestrel with lactose, starch, povidone, silicon dioxide and magnesium stearate is unlikely to create strong proprietary protection by itself. Patentability would require more than simply naming standard excipients. A defensible formulation patent would generally need a specific composition range, measurable performance advantage, stability result, dissolution profile or manufacturing feature.

Potentially protectable areas include:

• Improved low-dose content uniformity
• Moisture-resistant tablet architecture
• Enhanced dissolution under biorelevant conditions
• Reduced degradation impurities
• Direct-compression processing
• Alternative particle engineering
• Taste-masked or orally disintegrating dosage forms
• Heat-stable packaging and product combinations

These features have commercial value only if they solve a measurable problem and survive obviousness, enablement and written-description scrutiny.

When does AfterPill lose exclusivity?

AfterPill does not appear to have a conventional branded-drug exclusivity profile comparable to a new chemical entity. The product competes in a mature generic market where exclusivity is primarily commercial rather than patent-based.

Exclusivity type	Relevance to AfterPill
New chemical entity exclusivity	Not applicable to established levonorgestrel
Orphan-drug exclusivity	Not applicable
Pediatric exclusivity	Product-specific and unlikely to create durable market protection
New formulation exclusivity	Possible only if a qualifying FDA-approved innovation exists
ANDA approval exclusivity	Depends on the specific approval and any first-filer status
Patent exclusivity	No clear blocking patent identified for the conventional product
Brand or channel exclusivity	Contractual and commercially created rather than statutory

Generic entry is therefore possible whenever competing products receive approval and secure distribution. The main barriers are manufacturing qualification, quality compliance, retailer access, marketing expense and supply reliability.

What is the FDA and Orange Book status of AfterPill?

FDA status must be determined from the current product-specific listing because brand names, applicants, labelers and NDC numbers can change. The FDA Drugs@FDA database and Orange Book identify approved applications, reference listed drugs, patents and exclusivity information.[2,3]

For commercial diligence, the key checks are:

• Whether AfterPill has a current FDA-approved application.
• The applicant and manufacturer of record.
• The applicable NDC listing.
• The reference listed drug.
• Current prescribing or consumer labeling.
• Orange Book patent and exclusivity entries.
• Whether the marketed product is distributed under another approved labeler.
• Whether the product is sold through a lawful OTC or prescription channel.

A marketed product name alone does not establish approval ownership or Orange Book listing status.

Which companies compete with AfterPill?

Competition is fragmented across branded, generic, pharmacy and digital-health channels. Key competitors include Plan B One-Step and several generic levonorgestrel products marketed under names such as Take Action, My Choice, EContra EZ and Option 2. Retailers also sell store-brand or private-label equivalents.

Competitive factor	AfterPill opportunity
Price	Compete below branded Plan B through low-cost sourcing
Availability	Use direct shipping and advance-purchase inventory
Privacy	Offer discreet packaging and neutral fulfillment
Convenience	Integrate with telehealth and digital ordering
Trust	Emphasize FDA-compliant labeling and clear instructions
Institutional access	Supply clinics, campuses and public-health programs
Brand differentiation	Use packaging, service and channel positioning rather than formulation claims

The principal competitive threat is not a technologically superior tablet. It is a lower-priced generic with broader retail distribution or a platform that combines consultation, payment and rapid delivery.

What generic launch risks exist?

A new generic or private-label entrant could launch without overcoming a substantial patent barrier. Launch risk is concentrated in execution:

• Failure to achieve bioequivalence.
• Blend-uniformity failures caused by the low active dose.
• Dissolution drift during stability studies.
• Tablet capping, sticking or friability.
• API supply interruptions.
• Inadequate impurity controls.
• Labeling or promotional violations.
• Retailer reluctance to stock a low-margin product.
• Competition from emergency contraception alternatives, including ulipristal acetate and copper intrauterine devices.

A Paragraph IV challenge is less central for an established levonorgestrel product than for a recently launched branded drug. If a product-specific patent is listed, an ANDA applicant could use a Paragraph IV certification, but the practical significance depends on the patent’s validity, enforceability and claim scope.[4]

How does AfterPill compare with other emergency contraceptives?

Product	Active ingredient	Main formulation	Key commercial distinction
AfterPill	Levonorgestrel	Immediate-release tablet	Access, price and direct fulfillment
Plan B One-Step	Levonorgestrel	Immediate-release tablet	Brand recognition and retail presence
Generic levonorgestrel products	Levonorgestrel	Immediate-release tablet	Lower price and private-label flexibility
ella	Ulipristal acetate	Immediate-release tablet	Different pharmacology and prescription-related channel history
Copper IUD	Copper device	Intrauterine delivery	Long-term contraception and clinical placement

Levonorgestrel products compete on affordability and availability. Ulipristal acetate and copper IUDs have different clinical and operational profiles and should not be treated as direct formulation substitutes.

What licensing and manufacturing opportunities exist?

The most attractive licensing model is a finished-dose or contract-manufacturing arrangement with an established oral-solid-dose manufacturer. A licensee can commercialize AfterPill under a private label while the manufacturer retains responsibility for production, testing and quality systems.

Relevant deal structures include:

• Finished-product supply agreement.
• Private-label commercialization agreement.
• Exclusive channel license.
• Regional distribution license.
• Technology-transfer agreement for a differentiated tablet.
• Co-development of a heat-stable or orally disintegrating product.

Manufacturing value is strongest where the partner can provide low minimum order quantities, rapid packaging changes, reliable API sourcing and regulatory support. A formulation patent is not required for a profitable supply agreement, but it could improve negotiating leverage if it produces measurable stability, dissolution or manufacturing benefits.

Key Takeaways

• AfterPill is a conventional levonorgestrel 1.5 mg immediate-release tablet.
• The most likely excipient strategy uses standard diluents, binders, disintegrants, glidants and lubricants.
• Content uniformity is the central technical risk because levonorgestrel is present at a low dose.
• Excipient innovation is less commercially important than packaging, supply reliability and distribution.
• The product has limited practical patent exclusivity and faces a mature generic market.
• The strongest commercial opportunities are direct-to-consumer fulfillment, telehealth, private label, institutional supply and vending-compatible access.
• Exact FDA approval, NDC, Orange Book and current excipient data must be tied to the active product record and labeler.
• Manufacturing-process and packaging patents may matter even when active-ingredient patents do not.

FAQs

Is AfterPill the same as Plan B One-Step?

AfterPill and Plan B One-Step use the same active ingredient, levonorgestrel, at the 1.5 mg emergency-contraceptive strength. They may differ in manufacturer, excipient composition, packaging, price, distribution and labeling details.

Can AfterPill be reformulated as an orally disintegrating tablet?

Yes, a reformulation could use superdisintegrants, taste-masking agents and modified compression processes. The commercial benefit would need to be demonstrated through dissolution, stability, palatability and regulatory studies.

Does lactose in an AfterPill-type formulation create a major commercial limitation?

Usually no. Lactose is widely used in oral tablets. A lactose-free formulation could still be attractive for specific consumer positioning, but it would add formulation, sourcing and validation work without necessarily improving emergency-contraception performance.

Could AfterPill be sold in automated vending machines?

Potentially. The product’s unit-dose format, compact packaging and room-temperature storage profile are compatible with vending distribution, subject to state law, product labeling, age-access rules, temperature controls and machine security.

Is a two-pack of levonorgestrel emergency contraception patentable?

A two-pack alone would generally provide weak patent protection. A defensible patent position would require a non-obvious package design, dispensing system, stability solution, adherence feature or other technical contribution.

References

1. U.S. Food and Drug Administration. (2013). FDA approves Plan B One-Step emergency contraceptive for use without a prescription. https://www.fda.gov

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov

3. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/

4. U.S. Food and Drug Administration. (2024). ANDA submissions: Content and format of an abbreviated new drug application. https://www.fda.gov

5. DailyMed. (2024). Levonorgestrel tablet product labeling. National Library of Medicine. https://dailymed.nlm.nih.gov/